{"id":54256,"date":"2026-01-15T21:41:00","date_gmt":"2026-01-15T13:41:00","guid":{"rendered":"https:\/\/flcube.com\/?p=54256"},"modified":"2026-01-15T21:41:01","modified_gmt":"2026-01-15T13:41:01","slug":"sino-biopharmaceutical-buys-hygieia-pharma-for-up-to-rmb-1-2-b-adding-sirna-platform-for-chronic-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54256","title":{"rendered":"Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB\u202f1.2\u202fB, Adding siRNA Platform for Chronic Diseases"},"content":{"rendered":"\n<p><strong>Sino Biopharmaceutical Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG:\u202f1177<\/a>) announced it has agreed to acquire a <strong>100\u202f% equity stake<\/strong> in <strong>Hygieia Pharmaceuticals<\/strong> for a <strong>maximum base consideration of RMB\u202f1.2\u202fbillion (USD\u202f172\u202fmillion)<\/strong>, adding a <strong>pipeline of innovative small interfering RNA (siRNA) drugs<\/strong> targeting weight loss, cardiovascular, and nervous system disorders to its portfolio.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Sino Biopharmaceutical Ltd. (HKEX:\u202f1177)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Hygieia Pharmaceuticals (private)<\/td><\/tr><tr><td><strong>Equity<\/strong><\/td><td>100\u202f% stake<\/td><\/tr><tr><td><strong>Base Consideration<\/strong><\/td><td>RMB\u202f1.2\u202fbillion (USD\u202f172\u202fmillion)<\/td><\/tr><tr><td><strong>Structure<\/strong><\/td><td>All\u2011cash transaction<\/td><\/tr><tr><td><strong>Payment<\/strong><\/td><td>To be completed upon regulatory approvals (expected Q2\u202f2026)<\/td><\/tr><tr><td><strong>Earn\u2011out<\/strong><\/td><td>Up to RMB\u202f300\u202fmillion in milestones tied to Phase\u202fIII initiation and NDA approvals<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-profile-amp-sirna-platform\">Target Profile &amp; siRNA Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology:<\/strong> <strong>Small interfering RNA (siRNA)<\/strong> platform enabling <strong>long\u2011lasting target gene silencing<\/strong> with single or infrequent administrations<\/li>\n\n\n\n<li><strong>Therapeutic Areas:<\/strong><\/li>\n\n\n\n<li><strong>Weight loss\/metabolism<\/strong><\/li>\n\n\n\n<li><strong>Cardiovascular\/cerebrovascular<\/strong><\/li>\n\n\n\n<li><strong>Nervous system disorders<\/strong><\/li>\n\n\n\n<li><strong>Pipeline:<\/strong> <strong>4 clinical\u2011stage assets<\/strong> and <strong>10+ preclinical molecules<\/strong> with <strong>first\u2011in\u2011class (FIC) or best\u2011in\u2011class (BIC) potential<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-pipeline-assets\">Core Pipeline Assets<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Target<\/th><th>Dosing<\/th><th>Indication<\/th><th>Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>Kylo\u201111<\/strong><\/td><td>Lp(a) siRNA<\/td><td><strong>Once yearly<\/strong><\/td><td>Cardiovascular disease<\/td><td><strong>Phase\u202fII<\/strong><\/td><\/tr><tr><td><strong>Kylo\u201112<\/strong><\/td><td>APOC3 siRNA<\/td><td><strong>Every 6 months<\/strong><\/td><td>Hypertriglyceridemia (HTG), FCS<\/td><td><strong>Phase\u202fII\u2011ready<\/strong><\/td><\/tr><tr><td><strong>Preclinical<\/strong><\/td><td>Undisclosed siRNA<\/td><td><strong>Once yearly<\/strong><\/td><td>Obesity<\/td><td>Preclinical<\/td><\/tr><tr><td><strong>Preclinical<\/strong><\/td><td>Undisclosed siRNA<\/td><td><strong>Every 6 months<\/strong><\/td><td>Alzheimer\u2019s disease<\/td><td>Preclinical<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Hyperlipidemia Patients (Lp(a) elevation)<\/strong><\/td><td>25\u202fmillion<\/td><td>90\u202fmillion<\/td><\/tr><tr><td><strong>Severe HTG\/FCS Patients<\/strong><\/td><td>1.2\u202fmillion<\/td><td>4.5\u202fmillion<\/td><\/tr><tr><td><strong>Obesity (Class\u202fII\/III)<\/strong><\/td><td>85\u202fmillion<\/td><td>650\u202fmillion<\/td><\/tr><tr><td><strong>Alzheimer\u2019s Disease<\/strong><\/td><td>10\u202fmillion<\/td><td>55\u202fmillion<\/td><\/tr><tr><td><strong>siRNA Market (2030E)<\/strong><\/td><td>\u00a528\u202fbillion<\/td><td>$18\u202fbillion<\/td><\/tr><tr><td><strong>Hygieia Peak Revenue (2032E)<\/strong><\/td><td>\u00a54.2\u202fbillion<\/td><td>$2.8\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Moat:<\/strong> Hygieia\u2019s <strong>ultra\u2011long\u2011acting dosing<\/strong> (once yearly for Lp(a), every 6 months for APOC3) vs. competitors requiring <strong>monthly or quarterly injections<\/strong> (e.g., Novartis\u2019s Leqvio)<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Acquisition provides Sino Biopharmaceutical with <strong>first\u2011in\u2011China siRNA platform<\/strong>, leapfrogging domestic competitors in chronic disease RNA therapeutics<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-synergies\">Strategic Positioning &amp; Synergies<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sino\u2019s Platform:<\/strong> Complements Sino\u2019s existing <strong>metabolic disease franchise<\/strong> (diabetes, NASH) and <strong>CNS pipeline<\/strong> (stroke, Parkinson\u2019s)<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Sino\u2019s <strong>Shanghai biologics facility<\/strong> will integrate Hygieia\u2019s <strong>siRNA conjugation and LNP formulation<\/strong> capabilities by 2027<\/li>\n\n\n\n<li><strong>Commercial Reach:<\/strong> Sino\u2019s <strong>3,000\u2011person sales force<\/strong> targeting tier\u20112\/3 hospitals can rapidly launch Kylo\u201111\/12 upon approval<\/li>\n\n\n\n<li><strong>Global Ambitions:<\/strong> Hygieia\u2019s platform enables <strong>ex\u2011China licensing<\/strong> to MNCs; Sino plans <strong>US IND filings<\/strong> for Kylo\u201111 in <strong>2027<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding acquisition completion, pipeline development timelines, and revenue forecasts for Hygieia\u2019s siRNA platform. Actual results may differ due to regulatory approval timelines, clinical trial outcomes, and competitive dynamics in the RNA therapeutics market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011300488_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026011300488_c.\"><\/object><a id=\"wp-block-file--media-83874ebe-e3cb-4626-b8f0-bd9af0d7eff6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011300488_c.pdf\">2026011300488_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011300488_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-83874ebe-e3cb-4626-b8f0-bd9af0d7eff6\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Ltd. (HKG:\u202f1177) announced it has agreed to acquire a 100\u202f% equity stake in&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[908,64,313],"class_list":["post-54256","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-1177","tag-rnai-aso","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB\u202f1.2\u202fB, Adding siRNA Platform for Chronic Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Ltd. (HKG:\u202f1177) announced it has agreed to acquire a 100\u202f% equity stake in Hygieia Pharmaceuticals for a maximum base consideration of RMB\u202f1.2\u202fbillion (USD\u202f172\u202fmillion), adding a pipeline of innovative small interfering RNA (siRNA) drugs targeting weight loss, cardiovascular, and nervous system disorders to its portfolio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54256\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB\u202f1.2\u202fB, Adding siRNA Platform for Chronic Diseases\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Ltd. (HKG:\u202f1177) announced it has agreed to acquire a 100\u202f% equity stake in Hygieia Pharmaceuticals for a maximum base consideration of RMB\u202f1.2\u202fbillion (USD\u202f172\u202fmillion), adding a pipeline of innovative small interfering RNA (siRNA) drugs targeting weight loss, cardiovascular, and nervous system disorders to its portfolio.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54256\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T13:41:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-15T13:41:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54256#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54256\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB\u202f1.2\u202fB, Adding siRNA Platform for Chronic Diseases\",\"datePublished\":\"2026-01-15T13:41:00+00:00\",\"dateModified\":\"2026-01-15T13:41:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54256\"},\"wordCount\":423,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 1177\",\"RNAi \\\/ ASO\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54256#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54256\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54256\",\"name\":\"Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB\u202f1.2\u202fB, Adding siRNA Platform for Chronic Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-15T13:41:00+00:00\",\"dateModified\":\"2026-01-15T13:41:01+00:00\",\"description\":\"Sino Biopharmaceutical Ltd. (HKG:\u202f1177) announced it has agreed to acquire a 100\u202f% equity stake in Hygieia Pharmaceuticals for a maximum base consideration of RMB\u202f1.2\u202fbillion (USD\u202f172\u202fmillion), adding a pipeline of innovative small interfering RNA (siRNA) drugs targeting weight loss, cardiovascular, and nervous system disorders to its portfolio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54256#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54256\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54256#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB\u202f1.2\u202fB, Adding siRNA Platform for Chronic Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB\u202f1.2\u202fB, Adding siRNA Platform for Chronic Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Ltd. (HKG:\u202f1177) announced it has agreed to acquire a 100\u202f% equity stake in Hygieia Pharmaceuticals for a maximum base consideration of RMB\u202f1.2\u202fbillion (USD\u202f172\u202fmillion), adding a pipeline of innovative small interfering RNA (siRNA) drugs targeting weight loss, cardiovascular, and nervous system disorders to its portfolio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54256","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB\u202f1.2\u202fB, Adding siRNA Platform for Chronic Diseases","og_description":"Sino Biopharmaceutical Ltd. (HKG:\u202f1177) announced it has agreed to acquire a 100\u202f% equity stake in Hygieia Pharmaceuticals for a maximum base consideration of RMB\u202f1.2\u202fbillion (USD\u202f172\u202fmillion), adding a pipeline of innovative small interfering RNA (siRNA) drugs targeting weight loss, cardiovascular, and nervous system disorders to its portfolio.","og_url":"https:\/\/flcube.com\/?p=54256","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-15T13:41:00+00:00","article_modified_time":"2026-01-15T13:41:01+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54256#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54256"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB\u202f1.2\u202fB, Adding siRNA Platform for Chronic Diseases","datePublished":"2026-01-15T13:41:00+00:00","dateModified":"2026-01-15T13:41:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54256"},"wordCount":423,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 1177","RNAi \/ ASO","Sino Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54256#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54256","url":"https:\/\/flcube.com\/?p=54256","name":"Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB\u202f1.2\u202fB, Adding siRNA Platform for Chronic Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-15T13:41:00+00:00","dateModified":"2026-01-15T13:41:01+00:00","description":"Sino Biopharmaceutical Ltd. (HKG:\u202f1177) announced it has agreed to acquire a 100\u202f% equity stake in Hygieia Pharmaceuticals for a maximum base consideration of RMB\u202f1.2\u202fbillion (USD\u202f172\u202fmillion), adding a pipeline of innovative small interfering RNA (siRNA) drugs targeting weight loss, cardiovascular, and nervous system disorders to its portfolio.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54256#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54256"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54256#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB\u202f1.2\u202fB, Adding siRNA Platform for Chronic Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54256"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54256\/revisions"}],"predecessor-version":[{"id":54259,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54256\/revisions\/54259"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}